GENE BIOTHERAPEUTICS PARTNERS WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO MANUFACTURE GENERX [Ad5FGF-4] PHASE 3 ANGIOGENIC GENE THERAPY PRODUCT CANDIDATE FOR REFRACTORY ANGINA
2021-04-26
SAN DIEGO, CA – April 26, 2021 – Gene Biotherapeutics Inc. (OTC: CRXM) announced today that it has entered into an agreement with FUJIFILM Diosynth Biotechnologies (“FDB”) to manufacture the Generx [Ad5FGF-4] angiogenic gene therapy product candidate for Phase 3 clinical evaluation for the treatment of refractory angina due to late-stage coronary artery disease. Manufacturing operations will be conducted at FDB’s facilities in College Station, TX where FDB will perform technology transfer and process development activities for Phase 3 clinical and commercial-scale GMP manufacturing of Generx.